945003-38-3

Basic information

• Product Name: 3-Methoxy-4-(trifluoromethyl)benzaldehyde
• Synonyms: Benzaldehyde, 3-methoxy-4-(trifluoromethyl)-
• CAS NO: 945003-38-3
• Molecular Formula: C₉H₇F₃O₂
• Molecular Weight: 204.15
• Mol File: 945003-38-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Refractive Index: 1.4880
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-Methoxy-4-(trifluoromethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methoxy-4-(trifluoromethyl)benzaldehyde(945003-38-3)
• EPA Substance Registry System: 3-Methoxy-4-(trifluoromethyl)benzaldehyde(945003-38-3)

Safety Data

• Hazardous Substances Data: 945003-38-3(Hazardous Substances Data)

Usage

Description

3-Methoxy-4-(trifluoromethyl)benzaldehyde is an organic compound characterized by the presence of a methoxy group at the 3-position and a trifluoromethyl group at the 4-position on a benzene ring. It is an aromatic aldehyde with the molecular formula C8H6F3O2.

Uses

Used in Pharmaceutical Industry:
3-Methoxy-4-(trifluoromethyl)benzaldehyde is used as a reactant for the preparation of 2-methoxyacylhydrazones, which are selective PDE10A inhibitors. These inhibitors play a crucial role in the development of treatments for various neurological and psychiatric disorders, such as schizophrenia and Huntington's disease, by modulating the activity of phosphodiesterase 10A (PDE10A) enzyme.

Upstream product

• 115754-21-7 3-fluoro-4-(trifluoromethyl)benzoic acid 
• 141-52-6 sodium ethanolate 
• 447-93-8 3-methoxy-4-(trifluoromethyl)benzonitrile 

Downstream Products

• 951231-90-6 (E)-4-(3-methoxy-4-trifluoromethyl-phenyl)-but-3-en-2-one 
• 1207549-33-4 C₂₀H₁₉F₃N₂O₅ 
• 945003-39-4 2-(cyclopropylamino)-4-hydroxy-6-(3-methoxy-4-(trifluoromethyl)phenyl)pyrimidine-5-carbonitrile 

Relevant articles and documents

PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.